Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock

20 Feb 2026, 22:56 by Tristan Rich · The Markets Daily

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) EVP Catherine Doherty sold 1,433 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $204.83, for a total value of $293,521.39. Following the sale, the executive vice president owned 68,402 shares of the company’s stock, valued at $14,010,781.66. The trade was a 2.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Quest Diagnostics Trading Down 0.1%

DGX stock traded down $0.16 during midday trading on Friday, reaching $202.28. 642,015 shares of the company’s stock traded hands, compared to its average volume of 1,114,914. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.04 and a quick ratio of 0.96. Quest Diagnostics Incorporated has a fifty-two week low of $157.20 and a fifty-two week high of $213.20. The business has a 50-day moving average price of $185.18 and a two-hundred day moving average price of $183.41. The company has a market capitalization of $22.50 billion, a P/E ratio of 23.12, a PEG ratio of 2.64 and a beta of 0.66.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.35 by $0.07. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. The business had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.75 billion. During the same quarter last year, the firm posted $2.23 EPS. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. Equities research analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Stockholders of record on Monday, April 6th will be given a $0.86 dividend. The ex-dividend date of this dividend is Monday, April 6th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. This represents a $3.44 annualized dividend and a dividend yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.57%.

Quest Diagnostics announced that its board has initiated a share repurchase plan on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 4.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Mizuho upped their price target on Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Citigroup raised their price target on shares of Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Barclays lifted their price target on shares of Quest Diagnostics from $210.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Truist Financial upped their price objective on shares of Quest Diagnostics from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Finally, UBS Group raised their target price on Quest Diagnostics from $190.00 to $210.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Eight equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $210.29.

Check Out Our Latest Research Report on DGX

Hedge Funds Weigh In On Quest Diagnostics

Institutional investors have recently modified their holdings of the company. Quattro Advisors LLC bought a new stake in Quest Diagnostics during the 4th quarter valued at $25,000. JFS Wealth Advisors LLC increased its holdings in shares of Quest Diagnostics by 114.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares during the period. Sittner & Nelson LLC bought a new stake in shares of Quest Diagnostics during the fourth quarter valued at about $29,000. True Wealth Design LLC lifted its holdings in Quest Diagnostics by 369.7% in the third quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after purchasing an additional 122 shares during the period. Finally, DV Equities LLC bought a new position in Quest Diagnostics in the 4th quarter valued at about $27,000. Institutional investors own 88.06% of the company’s stock.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.